SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 27, 2022 for Raksha Sudhir Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Postal Ballot Notice and voting details SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company's Code of Conduct for Prevention of Insider Trading, the window closure for trading by Designated Persons of the Company (along with his/her immediate relatives or any person with whom he/she shares a material financial relationship), shall be with effect from Sunday, January 1, 2023 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022. The date of the Board Meeting of the Company for declaration of the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 will be intimated in due course. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Sustainability Report 2021-22
Submission of Sustainability Report of Sun Pharmaceutical Industries Limited ('the Company') for the financial year 2021-22 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Business Responsibility and Sustainability Reporting (BRSR)
Submission of Sustainability Report of Sun Pharmaceutical Industries Limited ('the Company') for the financial year 2021-22 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
This is to inform you that the Company is conducting a Postal Ballot seeking approval of the shareholders, by way of a Special Resolution, for appointment of Mr. Sanjay Asher (DIN: 00008221) as an Independent Director of the Company for a term commencing from November 1, 2022 till March 31, 2025. This intimation is being filed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and a copy of the Postal Ballot Notice is enclosed herewith. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On Halol Facility
This is in continuation to our communications dated May 10, 2022, August 13, 2022 and December 08, 2022 regarding the USFDA inspection at the Company's Halol (Gujarat, India) facility from April 26 to May 9, 2022. We now wish to inform you that the Company has received Warning Letter from USFDA for the Halol facility. The Warning Letter summarizes violations with respect to Current Good Manufacturing Practice (cGMP) regulations. USFDA shall make public the contents of the Warning Letter in due course. As per our communication dated December 08, 2022, the Halol facility was placed under Import Alert by USFDA. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Lis ting Obligations and Disclosure Requirements) Regulations, 2015